12th Nov 2007 08:24
Genus PLC12 November 2007 12 November 2007 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, JAPAN, CANADA, AUSTRALIA OR THE REPUBLIC OF IRELAND Genus plc ("Genus" or "the Company") Commencement of trading on the Official List Genus plc, a world leading animal genetics company, is pleased to announce thatadmission to the Official List of the UK Listing Authority and the London StockExchange's main market for listed securities of 59,204,190 ordinary shares of 10pence ("Ordinary Shares") has occurred ("Admission") and that trading in itsOrdinary Shares became effective from 8.00 am today. The Company's FTSEclassification is Biotechnology. Copies of the prospectus dated 6 November 2007, published in connection withAdmission are available from the "Investors" section of the Company's website atwww.genusplc.com. The prospectus has also been submitted to the UKLA's DocumentViewing Facility situated at: Financial Services Authority, 25 The NorthColonnade, Canary Wharf, London, E14 5HS.Enquiries: Genus plc Tel: 01256 345970Richard Wood, Chief ExecutiveMartin Boden, Finance Director Landsbanki Securities (UK) Limited Tel: 020 7426 9000Sponsor & Joint BrokerShaun Dobson Buchanan Communications Tel: 020 7466 5000Charles Ryland / Suzanne Brocks About Genus Genus creates and sells added value products for livestock farming and foodproducers by creating advances to animal breeding through biotechnology. Itsnon-Genetically Modified Organism (GMO) technology is applicable across alllivestock species but is only commercialised by Genus in the bovine and porcinefarming sectors. Genus' worldwide sales are made in seventy countries under the trade marks "ABS"(dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animalswith superior genetics to those animals currently in production. Customersproduce offspring with greater production efficiency, milk and meat output andquality and use these to supply the global dairy and meat supply chain. Genus' competitive edge has been created from the ownership and control ofproprietary lines of breeding animals, the biotechnology used to improve themand the Group's global production and distribution network. Headquartered in Basingstoke, England, Genus companies operate in 30 countrieson five continents, with research laboratories located in Madison, USA. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Genus